Cadwell Industries range of neurodiagnostic solutions
John Cadwell, BSEE, MD, saw a need for innovative and reliable neurophysiology instruments during his residency at the University of Washington School of Medicine in Seattle, Washington, USA. John used his experience in electrical engineering and medicine to design the world’s first microprocessor-controlled EMG instrument. John partnered with his brother, Carl Cadwell, DDS, and together they formed Cadwell in 1979. Throughout the years, Cadwell has grown its neurodiagnostic offerings into EEG, IONM and PSG.
Today, Cadwell employs more than 110 people at headquarters in research, hardware design, software design, assembly, marketing, distribution, sales support, and customer support. A network of sales and support representatives serve the U.S.A., and international managers in China, Singapore, the Netherlands, and Dubai serve our international distributors.
Cadwell’s range of products include the UK’s most popular NCS/EMG device the Sierra Summit which is now used in the majority of teaching hospitals in the UK & Ireland, the latest Arc EEG solutions including the Apollo with QVM3 Home Video ambulatory solution and the most advanced Intra-operative neuro-monitoring system Cascade IOMAX which can provide up to 80 channels of neuromonitoring.
Vascular Diagnostic Solutions
Atys Medical’s range of transcranial and peripheral vascular solutions
During the last 30 years Atys Medical have kept setting significant milestones in Vascular and Neurovascular solutions
In 1985, Atys introduced the world’s first device that can simultaneously monitor blood flow velocity in the middle cerebral artery and cardiac output.
In 2004, Atys marketed the first portable high resolution ultrasound scanner for skin imaging (melanoma assessment), the DERMCUP.
In 2009, Atys launched the SYSTOE on the market. SYSTOE is the first automated and affordable device that measures reliably toe systolic pressure. SYSTOE allows improving the early diagnosis of peripheral arterial disease especially among patients at higher risks as elderly patients and diabetics.
In 2012, thanks to a fruitful cooperation with Dr Rune Aaslid, Atys were able to market the first transcranial Doppler Holter. This portable, light and autonomous device, TCD-X, can record transcranial Doppler signal on patients “in action”. The innovation was double as the TCD-X was also fitted with one of the first two robotic transcranial probes available on the market.
From 2016, all of Atys’ desktop transcranial Doppler devices can be fitted with one or two robotic probes.
The Atys Waki R3 TCD solution allows the user to benefit from unique robotic probe technology which coupled with the advanced software detection and correction utility, allows users enhanced and more robust signal acquisition during monitoring of the vessels.